The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion
Open accessAbstract
Suppression of antitumor immune responses is one of the main mechanisms by which tumor cells escape from destruction by the immune system. Myeloid-derived suppressor cells (MDSCs) represent the main immunosuppressive cells present in the tumor microenvironment (TME) that sustain cancer progression. MDSCs are a heterogeneous group of immature myeloid cells with a potent activity against T-cell. Studies in mice have demonstrated that MDSCs accumulate in several types of cancer where they promote invasion, angiogenesis, and metastasis formation and inhibit antitumor immunity. In addition, different clinical studies have shown that MDSCs levels in the peripheral blood of cancer patients correlates with tumor burden, stage and with poor prognosis in multiple malignancies. Thus, MDSCs are the major obstacle to many cancer immunotherapies and their targeting may be a beneficial strategy for improvement the efficiency of immunotherapeutic interventions. However, the great heterogeneity of these cells makes their identification in human cancer very challenging. Since both the phenotype and mechanisms of action of MDSCs appear to be tumor-dependent, it is important to accurately characterized the precise MDSC subsets that have clinical relevance in each tumor environment to more efficiently target them. In this review we summarize the phenotype and the suppressive mechanisms of MDSCs populations expanded within different tumor contexts. Further, we discuss about their clinical relevance for cancer diagnosis and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–265 of 265
Wu, C., Hsieh, C., Lin, C., Chen, W., Hong, J., & Chen, M. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0916-x · Cited by 93
Ye, T., Yang, F., Zhu, Y., Li, Y., Lei, Q., Song, X., Xia, Y., Xiong, Y., Zhang, L., Wang, N., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.452 · Cited by 92
Safarzadeh, E., Hashemzadeh, S., Duijf, P. H. G., Mansoori, B., Khaze, V., Mohammadi, A., Kazemi, T., Yousefi, M., Asadi, M., Mohammadi, H., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26896 · Cited by 90
Chi, N., Tan, Z., Ma, K., Bao, L., & Yun, Z. (2014) · PubMed · Cited by 88
Lin, S., Wang, J., Wang, L., Wen, J., Guo, Y., Qiao, W., Zhou, J., Xu, G., & Zhi, F. (2017) · Europe PMC (PubMed Central) · Cited by 82
CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D
Bruns, H., Böttcher, M., Qorraj, M., Fabri, M., Jitschin, S., Dindorf, J., Busch, L., Jitschin, R., Mackensen, A., & Mougiakakos, D. (2016) · Leukemia · doi:10.1038/leu.2016.378 · Cited by 81
Lee, J., Seo, J., Kim, Y., Kim, Y., Ko, H., & Kang, C. (2011) · International Journal of Cancer · doi:10.1002/ijc.26411 · Cited by 80
Inflammation and Prostate Cancer
Vasto, S., Carruba, G., Candore, G., Italiano, E., Bona, D. D., & Caruso, C. (2008) · Future Oncology · doi:10.2217/14796694.4.5.637 · Cited by 80
Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer
Liu, D., You, M., Xu, Y., Li, F., Zhang, D., Li, X., & Hou, Y. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.07.035 · Cited by 80
Myeloid cells in circulation and tumor microenvironment of breast cancer patients
Toor, S. M., Khaja, A. S. S., Salhat, H. E., Faour, I., Kanbar, J., Quadri, A., Mohamed, A., & Elkord, E. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1977-z · Cited by 80
Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies
Bujanda, Z. A. L., & Drake, C. G. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-491rr · Cited by 78
Heuvers, M. E., Muskens, F., Bezemer, K., Lambers, M. E. H., Dingemans, A. C., Groen, H. J. M., Smit, E. F., Hoogsteden, H. C., Hegmans, J. P., & Aerts, J. G. J. V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.06.005 · Cited by 76
Toor, S. M., Khaja, A. S. S., Salhat, H. E., Bekdache, O., Kanbar, J., Jaloudi, M., & Elkord, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00560 · Cited by 74
Gao, X., Tian, L., Wu, J., Ma, X., Zhang, C., Zhou, Y., Sun, Y., Hu, B., Qiu, S., Zhou, J., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12831 · Cited by 72
Zheng, Y., Xu, M., Xiao, L., Jia, J., Fan, K., & Lai, G. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.10.035 · Cited by 71
Roth, G. S., & Decaens, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.010 · Cited by 70
Shen, P., Wang, A., He, M., Wang, Q., & Zheng, S. (2013) · Hepatology Research · doi:10.1111/hepr.12167 · Cited by 67
Chang, C. F., Yang, Y., Chiu, C.-J., Lu, L., Liao, C., Liang, C., Hsu, C., & Cheng, A. (2017) · International Journal of Cancer · doi:10.1002/ijc.31216 · Cited by 67
Brusa, D., Simone, M., Gontero, P., Spadi, R., Racca, P., Micari, J., Degiuli, M., Carletto, S., Tizzani, A., & Matera, L. (2013) · International Journal of Urology · doi:10.1111/iju.12086 · Cited by 66
Analysis of prognostic factors for melanoma patients
Lideikaitė, A., Mozūraitienė, J., & Letautienė, S. R. (2017) · Acta medica Lituanica · doi:10.6001/actamedica.v24i1.3460 · Cited by 66
Silva, A. P. S., Coelho, P. V., Anazetti, M. C., & Simioni, P. U. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1249551 · Cited by 65
Weiss, J. M., Subleski, J. J., Back, T., Chen, X., Watkins, S. K., Yagita∥, H., Sayers, T. J., Murphy, W. J., & Wiltrout, R. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400404 · Cited by 63
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
Sharma, B., Singh, S., Varney, M. L., & Singh, R. K. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003652471 · Cited by 61
Elwan, N. M., Salem, M. L., Kobtan, A. A., El-Kalla, F., Mansour, L., Yousef, M., Al-Sabbagh, A., Zidan, A. A., & Abd-Elsalam, S. M. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1407787 · Cited by 59
Targeting Myeloid-Derived Suppressor Cells in Cancer
Anani, W. Q., & Shurin, M. R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_8 · Cited by 59
Creelan, B., Gabrilovich, D. I., Gray, J. E., Williams, C. C., Tanvetyanon, T., Haura, E. B., Weber, J. S., Gibney, G. T., Markowitz, J., Proksch, J. W., et al. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s136992 · Cited by 58
The innate immune architecture of lung tumors and its implication in disease progression
Milette, S., Fiset, P., Walsh, L. A., Spicer, J. D., & Quail, D. F. (2019) · The Journal of Pathology · doi:10.1002/path.5241 · Cited by 58
Li, X., Xing, Y., Lei, A., Xiao, Q., Lin, Z., Hong, Y., Wu, X., & Zhou, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15456 · Cited by 57
Armstrong, A. J., Häggman, M., Stadler, W. M., Gingrich, J. R., Assikis, V. J., Polikoff, J. A., Damber, J. ‐., Belkoff, L. H., Nordle, Ö., Forsberg, G., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1581 · Cited by 56
The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients
Tobin, R. P., Davis, D. M., Jordan, K. R., & McCarter, M. D. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1016-449r · Cited by 56
Yang, R., Cai, T., Wu, X., Liu, Y., He, J., Zhang, X.-S., Ma, G., & Li, J. (2018) · Immunology · doi:10.1111/imm.12949 · Cited by 55
Hashimoto, A., Fukumoto, T., Zhang, R., & Gabrilovich, D. I. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02588-7 · Cited by 53
Qian, H., Chen, Y., & Yang, Y. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.28 · Cited by 52
Armstrong, A. J., Kaboteh, R., Carducci, M. A., Damber, J. ‐., Stadler, W. M., Hansen, M., Edenbrandt, L., Forsberg, G., Nordle, Ö., Пили, Р., et al. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.08.006 · Cited by 48
Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival
Panza, E., Cicco, P. D., Ercolano, G., Armogida, C., Scognamiglio, G., Anniciello, A. M., Botti, G., Cirino, G., & Ianaro, A. (2016) · Oncotarget · doi:10.18632/oncotarget.10976 · Cited by 48
Self-citationIsaacs, J. T. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.514262 · Cited by 47
Panza, E., Ercolano, G., Cicco, P. D., Armogida, C., Scognamiglio, G., Botti, G., Cirino, G., & Ianaro, A. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.008 · Cited by 44
Self-citationBoutté, A. M., McDonald, W. H., Shyr, Y., Li, Y., & Lin, P. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022446 · Cited by 43
Cicco, P. D., Ercolano, G., Rubino, V., Terrazzano, G., Ruggiero, G., Cirino, G., & Ianaro, A. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14824 · Cited by 43
Self-citationIDO inhibits T-cell function through suppressing Vav1 expression and activation
Li, R., Wei, F., Yu, J., Li, H., Ren, X., & Ren, X. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.14.8882 · Cited by 41
Regulating Tumor Myeloid-Derived Suppressor Cells by MicroRNAs
Chen, S., Zhang, Y., Kuzel, T. M., & Zhang, B. (2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.637 · Cited by 41
Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease
Netherby, C. S., & Abrams, S. I. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1963-5 · Cited by 41
Sun, J., Yu, J., Li, H., Yang, L., Wei, F., Yu, W., Liu, J., & Ren, X. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-82 · Cited by 39
Cicco, P. D., Sanders, T. J., Cirino, G., Maloy, K. J., & Ianaro, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00499 · Cited by 37
Self-citationChen, H., Libertini, S. J., George, M. D., Dandekar, S., Tepper, C. G., Al-Bataina, B., Kung, H.-J., Ghosh, P., & Mudryj, M. M. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0081 · Cited by 36
Alderman, C., Sehlaoui, A., Xiao, Z., & Yang, Y. (2016) · Tumor Biology · doi:10.1007/s13277-016-5271-z · Cited by 36
Ercolano, G., García-Garijo, A., Salomé, B., Gomez‐Cadena, A., Vanoni, G., Mastelic-Gavillet, B., Ianaro, A., Speiser, D. E., Romero, P. J., Trabanelli, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0504 · Cited by 35
Self-citationBreast cancer etiology by estrogen and progesterone receptors status: a review
Althuis, M. D., Fergenbaum, J., Sherman, M. E., García‐Closas, M., Madigan, M. P., & Brinton, L. A. (2003) · Annals of Epidemiology · doi:10.1016/s1047-2797(03)00136-4 · Cited by 34
Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
Regzedmaa, O., Zhang, H., Liu, H., & Chen, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s204577 · Cited by 34
Sanford, D. E., Porembka, M. R., Panni, R. Z., Mitchem, J. B., Belt, B. A., Plambeck-Suess, S. M., Lin, G., DeNardo, D. G., Fields, R. C., Hawkins, W. G., et al. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.43096 · Cited by 32
Garton, A. J., Seibel, S., Lopresti-Morrow, L., Crew, L., Janson, N., Mandiyan, S., Trombetta, E. S., Pankratz, S., LaVallee, T. M., & Gedrich, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0676 · Cited by 32
Chemotherapy for small cell lung cancer: a comprehensive review
Karim, S. M. M., & Zekri, J. (2012) · Oncology Reviews · doi:10.4081/oncol.2012.e4 · Cited by 31
Izhak, L., Wildbaum, G., Zohar, Y., Anunu, R., Klapper, L. N., Elkeles, A., Seagal, J., Yefenof, E., Ayalon-Soffer, M., & Karin, N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802746 · Cited by 30
Prognostic value of IL-6 in localized prostatic cancer.
Alcóver, J., Filella, X., Luqué, P., Molina, R., Izquierdo, L., Auge, J. M., & Alcaraz, A. (2010) · PubMed · Cited by 30
Hetta, H. F., Zahran, A. M., Mansor, S. G., Abdelmalek, M. O., Mekky, M. A., & Abbas, W. A. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25428 · Cited by 28
TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells
Dang, Y., Rutnam, Z. J., Dietsch, G. N., Lu, H., Yang, Y., Hershberg, R. M., & Disis, M. L. (2017) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ab0217-070r · Cited by 25
Stanojević, I., Miller, K., Sekulović, L. K., Mijušković, Ž. P., Zolotarevski, L. D., Jović, M., Gacevic, M., Djukic, M. M., Arsenijević, N., & Vojvodić, D. (2015) · International Immunology · doi:10.1093/intimm/dxv053 · Cited by 24
Yan, J., & Huang, J. (2014) · OncoImmunology · doi:10.4161/21624011.2014.953423 · Cited by 23
Motoshima, T., Komohara, Y., Horlad, H., Takeuchi, A., Maeda, Y., Tanoue, K., Kawano, Y., Harada, M., Takeya, M., & Eto, M. (2015) · Oncology Reports · doi:10.3892/or.2015.3893 · Cited by 23
Zhang, Y., Wang, J., Wang, W., Tian, J., Yin, K., Tang, X., Ma, J., Xu, H., & Wang, S. (2016) · Tumor Biology · doi:10.1007/s13277-016-5414-2 · Cited by 21
Chen, J., Wang, Z., Ding, Y., Huang, F., Huang, W., Lan, R., Chen, R., Wu, B., Fu, L., Yang, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00004 · Cited by 21
Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway
Shi, J., Wang, L., Zou, C., Xia, Y., Qin, S., Keller, E. T., Mizokami, A., Zhang, J., & Lü, Y. (2018) · Oncotarget · doi:10.18632/oncotarget.24104 · Cited by 15
Immunotherapy of Colorectal Cancer
Jäger, D., Halama, N., Zörnig, I., Klug, P., Krauß, J., & Haag, G.-M. (2016) · Oncology Research and Treatment · doi:10.1159/000446713 · Cited by 14
Mehra, N., Seed, G., Lambros, M. B. K., Sharp, A., Fontes, M. S., Crespo, M., Sumanasuriya, S., Yuan, W., Boysen, G., Riisnaes, R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw372.41 · Cited by 14
Pemetrexed and cyclophosphamide combination therapy for the treatment of non-small cell lung cancer.
Li, D., & He, S. (2015) · PubMed · Cited by 6
Cited by
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 460
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
Inflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata-Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 290
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
Metadata
- Authors
- De Cicco, P., Ercolano, G., & Ianaro, A.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-30
- Volume
- 11
- Pages
- 1680-1680
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3046152640
- Cited by
- 332
- References
- 265
- FWCI
- 14.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.